Related Experiment Video
Updated: Jul 7, 2026

Minimally Invasive Cisterna Magna Injection Model for Leptomeningeal Metastasis Studies in Mice
Published on: May 23, 2025
Myelomatous meningitis
Marc C Chamberlain1, Michael Glantz
1Department of Neurology, University of Washington, Fred Hutchinson Cancer Center, Seattle, Washington 98109, USA. ChambeMC@u.washington.edu
Background:
The most frequent nervous system complications of multiple myeloma are peripheral neuropathy and epidural spinal cord compression. Myelomatous meningitis (MM) has been considered rare. The current study was performed to characterize the clinical presentation, treatment, and outcome of MM.
Methods:
The study was a case series of 14 patients with cerebrospinal fluid (CSF)-positive MM who were treated at a tertiary care university medical center.
Results:
Fourteen patients with advanced multiple myeloma were treated with involved-field radiotherapy (to the brain in 5 patients and the spine in 6 patients) and intra-CSF chemotherapy (ventricular in 10 patients and lumbar in 4 patients). The best response to treatment included 6 partial responses and 8 patients with progressive disease. The median duration of response was 2.5 months (range, 0-6 months). Cause of death was progressive neurologic disease in 6 patients, combined systemic and neurologic disease in 6 patients, and systemic disease progression in 2 patients.
Conclusions:
MM is rare and morbid entity (6-month neurologic disease progression-free survival rate of 7%), and appears to be no more responsive to treatment than solid tumor carcinomatous meningitis.
Insights
Myelomatous meningitis (MM) is a rare complication of multiple myeloma. This study found MM to be a morbid entity with poor response to treatment and a low survival rate.
Area of Science:
- Neurology
- Oncology
- Hematology
Background:
- Nervous system complications in multiple myeloma (MM) include peripheral neuropathy and spinal cord compression.
- Myelomatous meningitis (MM) is considered a rare complication of MM.
Purpose of the Study:
- To characterize the clinical presentation of MM.
- To define the treatment strategies for MM.
- To evaluate the outcomes of MM patients.
Main Methods:
- A case series of 14 patients with cerebrospinal fluid (CSF)-positive MM.
- Treatment involved involved-field radiotherapy and intra-CSF chemotherapy.
- Patients were treated at a tertiary care university medical center.
Main Results:
- Six partial responses and 8 patients with progressive disease were observed.
- The median duration of response was 2.5 months.
- Causes of death included progressive neurologic disease, combined systemic and neurologic disease, and systemic disease progression.
Conclusions:
- MM is a rare and morbid entity with a 6-month progression-free survival rate of 7%.
- MM appears to have a similar treatment response rate as solid tumor carcinomatous meningitis.
Related Concept Videos
Bacterial Meningitis I: Introduction
Bacterial Meningitis
Bacterial Meningitis II: Pathophysiology
Viral Meningitis
Cryptococcal Meningitis
Encephalitis l: Introduction
